Printer Friendly

Provectus Biopharmaceuticals partners with POETIC for the study the potential of PV-10 in pediatric cancer.

M2 EQUITYBITES-December 9, 2016-Provectus Biopharmaceuticals partners with POETIC for the study the potential of PV-10 in pediatric cancer

(C)2016 M2 COMMUNICATIONS http://www.m2.com

Oncology company Provectus Biopharmaceuticals (OTCQB:PVCT) Thursday revealed a joint research agreement to study the potential of its PV-10 in pediatric cancer in partnership with POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium).

Under the partnership, Provectus and POETIC will jointly focus on pediatric applications of the former's PV-10 as a potential treatment for childhood cancers. PV-10 is an injectable formulation of Rose Bengal that is under investigation as an ablative immunotherapy for solid tumor cancers.

Provectus has reportedly received orphan drug designations of PV-10 from the US FDA for melanoma and hepatocellular carcinoma indications. It is conducting a Phase 3 clinical trial of PV-10 for locally advanced cutaneous melanoma.

This programme will involve collaboration with a number of NCI Cancer Centers that are part of the POETIC group including Memorial Sloan Kettering Cancer Center (MSK), Alberta Children's Hospital, and other top-tier cancer centers of excellence.

POETIC was founded by Dr Lia Gore at the University of Colorado Cancer Center and Dr Tanya Trippett at Memorial Sloan Kettering Cancer Center. POETIC is composed of ten large academic medical centres in North America that provide the collaborative and research strength needed to complete intensive phase I and II studies.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Dec 9, 2016
Words:234
Previous Article:Spotlight Innovation names new senior vice president of Regulatory Affairs and Compliance.
Next Article:Provectus Biopharmaceuticals partners with POETIC for the study the potential of PV-10 in paediatric cancer.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |